| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1032075271 |
| P356 | DOI | 10.1038/SJ.ONC.1201374 |
| P698 | PubMed publication ID | 9365234 |
| P5875 | ResearchGate publication ID | 13865099 |
| P50 | author | Mikhail Blagosklonny | Q17517010 |
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1889-1893 | |
| P577 | publication date | 1997-10-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Loss of function and p53 protein stabilization | |
| P478 | volume | 15 |
| Q44163171 | A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism |
| Q37492151 | A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1. |
| Q74529921 | A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers |
| Q40625177 | Abundant Expression of Spliced HDM2 in Hodgkin Lymphoma Cells does not Interfere with p14ARFand p53 Binding |
| Q34306523 | Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture |
| Q97558454 | Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer |
| Q46788559 | Chaperone-dependent stabilization and degradation of p53 mutants |
| Q35833179 | Cisplatin fails to induce puma mediated apoptosis in mucosal melanomas |
| Q47627937 | Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY. |
| Q54023194 | Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. |
| Q33959840 | Concerted regulation of wild-type p53 nuclear accumulation and activation by S100B and calcium-dependent protein kinase C. |
| Q53072244 | Correlation of High-Risk Soft Tissue Sarcoma Biomarker Expression Patterns with Outcome following Neoadjuvant Chemoradiation. |
| Q44102640 | Differentiation and growth potential of human ovarian surface epithelial cells expressing temperature-sensitive SV40 T antigen |
| Q34226063 | Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors |
| Q24529971 | Enhanced overexpression of an HIF-1/hypoxia-related protein in cancer cells. |
| Q37349459 | Epstein-Barr virus infection correlates with the expression of COX-2, p16(INK4A) and p53 in classic Hodgkin lymphoma |
| Q22254607 | Evidence that dynamin-2 functions as a signal-transducing GTPase |
| Q43816387 | FOXO3-mediated chemo-protection in high-stage neuroblastoma depends on wild-type TP53 and SESN3. |
| Q28361532 | Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones |
| Q33961759 | High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays |
| Q34124337 | Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs |
| Q74284148 | Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer |
| Q36292668 | Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significance |
| Q46699154 | Inhibition of plasminogen activator inhibitor-1 expression in vascular smooth muscle cells by protoporphyrins through a heme oxygenase-independent mechanism |
| Q40794489 | Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity |
| Q39170177 | Mechanisms of p53 restriction in Merkel cell carcinoma cells are independent of the Merkel cell polyoma virus T antigens. |
| Q40492947 | Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. |
| Q44573111 | Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase |
| Q35574969 | Mutual reinforcement of inflammation and carcinogenesis by the Helicobacter pylori CagA oncoprotein |
| Q23922085 | NF-kappaB prevents cells from undergoing Cr(VI)-induced apoptosis |
| Q54941625 | Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors. |
| Q64269842 | Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer |
| Q34539978 | P53: an ubiquitous target of anticancer drugs |
| Q52826331 | Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. |
| Q89449774 | Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients |
| Q36811577 | Phosphorylation-Dependent Regulation of the DNA Damage Response of Adaptor Protein KIBRA in Cancer Cells |
| Q34340573 | Pigmentation, Melanocyte Colonization, and p53 Status in Basal Cell Carcinoma |
| Q53404887 | Pituitary neoplasia induced by expression of human neurotropic polyomavirus, JCV, early genome in transgenic mice. |
| Q35450753 | Poly(ADP-ribosyl)ation of p53 contributes to TPEN-induced neuronal apoptosis |
| Q26824536 | Predictive biomarkers in precision medicine and drug development against lung cancer |
| Q38931100 | Proteasome inhibitors suppress the protein expression of mutant p53. |
| Q35116243 | Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy |
| Q41922591 | Regulation of BRCA1 by protein degradation |
| Q37730217 | Relationship between HPV and the biomarkers annexin A1 and p53 in oropharyngeal cancer |
| Q34740058 | Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. |
| Q61806604 | Synergistic activation of the NEU4 promoter by p73 and AP2 in colon cancer cells |
| Q92557155 | TIGAR promotes growth, survival and metastasis through oxidation resistance and AKT activation in glioblastoma |
| Q47298581 | The Tumor Suppressor p53 in Mucosal Melanoma of the Head and Neck |
| Q33771774 | The cellular response to p53: the decision between life and death |
| Q40258141 | The death domain kinase RIP has an important role in DNA damage-induced, p53-independent cell death |
| Q34096437 | The influence of Trp53 in the dose response of radiation-induced apoptosis, DNA repair and genomic stability in murine haematopoietic cells |
| Q73171130 | The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association |
| Q24550923 | ZBP-89 promotes growth arrest through stabilization of p53 |
| Q35600102 | gef gene expression in MCF-7 breast cancer cells is associated with a better prognosis and induction of apoptosis by p53-mediated signaling pathway |
| Q34832663 | microRNAs: short non-coding bullets of gain of function mutant p53 proteins |
| Q77957211 | p53 induction in normal human skin in vitro following exposure to solar simulated UV and UV-B irradiation |
| Q45332864 | p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer |
Search more.